Nova Biomedical Enhances Integrated Workflows for Cell Line Development with NanoCellect Acquisition

Nova Biomedical's Strategic Acquisition of NanoCellect

In a significant development within the biopharmaceutical landscape, Nova Biomedical has announced the acquisition of key assets from NanoCellect, a company renowned for its innovative microfluidic cell sorting technologies. This strategic move is set to enhance Nova Biomedical's existing capabilities in cell line development, providing an integrated framework to support biopharma workflows from the initial development phases all the way to manufacturing.

The acquisition centers around NanoCellect's flagship product, the NanoCellect® WOLF G2® platform, which specializes in gentle, microfluidic cell selection and isolation. This addition complements Nova Biomedical’s already robust Solentim portfolio, which focuses on clone creation, verification, and growth analysis. By integrating these technologies, Nova Biomedical aims to foster a highly cohesive approach to cell line development—linking cell selection, single-cell isolation, and reliable clone verification in one seamless process.

This expanded portfolio is poised to accelerate timelines for cell line development while improving clone selection outcomes. Concurrently, it establishes a stronger foundation for process development, scale-up procedures, and ultimate production efficiency.

Moreover, Nova Biomedical's suite includes formidable analytical solutions for monitoring cell cultures. Tools like BioProfile® FLEX2 for metabolite analysis, OsmoTECH® for osmolality measurement, and BioProfile® FAST CDV for cell counting and viability assessment serve as crucial checkpoints across the entire bioprocess workflow, from development to production.

With the integration of NanoCellect's innovative products, Nova Biomedical is actively advancing its strategy to offer a more interconnected technology portfolio. This will facilitate continuity, generate valuable insights, and improve decision-making throughout the lifecycle of bioprocessing.

According to John Luck, President of Nova Biomedical’s Biopharma division, "NanoCellect contributes a vital upstream capability to our portfolio, enhancing our ability to connect critical steps in cell line development. By merging cell sorting with clone isolation and a high-reliability verification system, alongside analytical checkpoints like cell culture monitoring and osmolality assessment, we empower our customers to swiftly identify suitable clones. This contributes to optimizing clone selection and achieving better performance throughout process development, scale-up, and production phases."

This acquisition marks a pivotal step towards building a more integrated and differentiated platform for cell line development and biotechnological process management. Nova Biomedical continues to affirm its commitment to delivering advanced analytical devices and solutions that enhance operational efficiency, product quality, and overall productivity within the biopharmaceutical sector.

About Nova Biomedical

Nova Biomedical is a global leader in advanced analytical equipment and solutions tailored for the biopharmaceutical and clinical markets. Their portfolio supports critical workflows in cell line development, process optimization, and manufacturing, driving improvements in customer productivity and operational effectiveness.

About NanoCellect

NanoCellect specializes in microfluidic cell sorting technologies designed for gentle and sterile cell isolation. Their platforms are instrumental in various applications, including cell line development, single-cell analysis, and cell therapy research.

For more information, visit Nova Biomedical’s website or contact their corporate communications department.